RNAZ TransCode Therapeutics: Earnings per share for the last twelve months
TransCode Therapeutics (RNAZ) develops durable RNA-based drugs, banking on stable demand in oncology and high margins. These developments establish a patent base for future monetization, as evidenced by the change in per-unit profit over the last 12 months. The value of -50.79 reflects the current metric volume, while the market currently prices in capital dilution risks due to the absence of current commercial revenue.
Analytical breakdowns for TransCode Therapeutics Inc. (RNAZ)
- stock price and consensus target price:
- company stock capitalization data:
- shareholders' equity book value data:
- debt and liquidity details:
Total Debt to Equity Ratio TransCode Therapeutics|RNAZ - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio TransCode|RNAZ - Company Cumulative Indebtedness|Debts to Book Capitalization TransCode Therapeutics, Inc.|RNAZ - Company Long-Term Loans and Borrowings|Company Short-Term Debts TransCode Therapeutics|Quick Liquidity transcodetherapeutics.com
- net income and valuation multiples indicators:
RNAZ - Final Profit|Projected Future Earnings TransCode Therapeutics|RNAZ - P/E Multiple|Future Price to Earnings TransCode|RNAZ - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple TransCode Therapeutics, Inc.|RNAZ - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months TransCode Therapeutics|RNAZ - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months transcodetherapeutics.com|RNAZ - Net earnings per one share growth for the current year|Earnings growth forecast for next year TransCode Therapeutics
Summary company analytics:transcodetherapeutics.com (RNAZ)
Stability of RNA component supplies through diversified channels provides TransCode Therapeutics (RNAZ) with operational resilience. Net income per share (TTM) measures the final financial result distributed across all equity shares over the year. This metric allows for an assessment of real business efficiency by excluding distortions from share issuances. It is critical for investors to see whether technological superiority converts into actual earnings. Analyzing the annual TTM earnings per share helps determine the growth rate of margins.
Competing companies
Tempus AI - Net earnings per share (EPS TTM)|qiagen.com (QGEN) - Net earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Corp (RGEN)|RNA (Avidity) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months CRSP (CRISPR)|Net earnings per share (EPS TTM) WGS|RARE - Net earnings per one share for the last twelve months|Beam Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year SRPT|TWST: Net earnings per share for the last 12 months|10x - Earnings per share for the last four quarters|NTLA: Net earnings per share (EPS TTM)|stoketherapeutics.com - Earnings per share for the trailing year|BLFS (BioLife Solutions) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Wave Life Sciences Ltd WVE|Earnings per share for the last twelve months Maze Tx (MAZE)|SION (Sionna Corp) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) PRME (Prime Medicine, Inc.)|Net earnings per share (EPS TTM) tayshagtx.com TSHA|QURE - Earnings per share for the last twelve months|Earnings per one share for the last 12 months MGTX|RGNX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Solid Corp (SLDB)|Net earnings per share for the last 12 months OCGN|Net earnings per share (EPS TTM) pacb.com|Net earnings per share for the last 12 months BNTC (Benitec Biopharma)|Earnings per share for the last four quarters DSGN|Net earnings per share (EPS TTM) RCKT (Rocket Pharmaceuticals Inc)|Net earnings per share for the last four quarters 4D Molecular Corp (FDMT)|Lexeo - Net earnings per share (EPS TTM)|Korro Bio, Inc. (KRRO) - Net earnings per share for the last 12 months|Editas Medicine (EDIT) - Earnings per share for the last twelve months|SLN - Net earnings per share for the last four quarters|Earnings per share for the last twelve months ProQR|CDXS: Earnings per share for the trailing year|Earnings per share for the last twelve months Sangamo Therapeutics (SGMO)|nautilus.bio - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) MGX (Metagenomi)|Net earnings per share (EPS TTM) Precision BioSciences Inc. DTIL|GBIO: Net earnings per share for the last 12 months|Earnings per one share for the last 12 months BOLD|XCUR: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months IMNN|Earnings per share for the last twelve months Phio Pharmaceuticals Corp|Earnings per share for the last 12 months MBIO (Mustang Bio Corp)|Net earnings per share (EPS TTM) BNGO|Net earnings per share (EPS TTM) Applied DNA Corp (APDN)|bluebird bio, Inc. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters IPA (ImmunoPrecise Antibodies Ltd)|OMGA - Earnings per share for the last twelve months|Earnings per share for the trailing year OMIC (Singular Genomics Systems, Inc.)|RGLS: Net earnings per share (EPS TTM)|Syros Pharmaceuticals, Inc (SYRS) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Telesis Bio, Inc.|Earnings per share for the last 12 months TCON (traconpharma.com)|Earnings per share for the last twelve months Unity Biotechnology, Inc. (UBX)
